Fig. 4: Peripheral blood cytokine profile in vivo.
From: TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
a Heatmap of 32 peripheral blood cytokines of tumor-free mice and mice challenged with 4T1 FUGW-FL tumors three weeks post orthotopic tumor implantation: tumor-free mice (healthy mice, no tumor implanted); tumor-bearing mice, vehicle (PBS) control (non-survivors), tumor-bearing mice, failed treatment (non-survivors), and tumor-bearing mice, long-term survivors. b Volcano plot highlighting detectable statistical difference between peripheral blood cytokines three weeks post orthotopic tumor challenge. c Heatmap of 32 peripheral blood cytokines of mice challenged with 4T1 FUGW-FL tumors 5 to 7 weeks post tumor implantation: tumor-bearing mice, vehicle (PBS) control (non-survivors) at week 5; tumor-bearing mice, failed treatment (non-survivors), weeks 5 to 7; and tumor-bearing mice, long-term survivors during weeks 6 and 7. d Volcano plot highlighting detectable statistical difference between peripheral blood cytokines taken between 5 and 7 weeks post orthotopic tumor challenge. e Heatmap of 32 peripheral blood cytokines of mice re-challenged with 4T1 FUGW-FL tumor: tumor naïve mice, tumor-bearing (non-survivors), tumor survivor mice, re-challenge failure (non-survivors) and tumor survivor mice, re-challenge survivor (long-term survivors) taken three weeks post orthotopic 4T1 FUGW-FL tumor implantation. f Volcano plot highlighting detectable statistical difference between peripheral blood-bourne cytokines taken three weeks post orthotopic tumor re-challenge.
